Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients with Advanced Lung Cancer

This trial is testing a personalized cell therapy called GT201 — where immune cells taken from a patient's own tumor (called tumor-infiltrating lymphocytes, or TILs) are grown in the lab and given back to fight the cancer — in people with advanced lung cancer. **You may be eligible if...** - You are between 18 and 70 years old - You have advanced non-small cell lung cancer (without certain driver gene mutations) that has not responded to first-line treatment, OR small cell lung cancer that has not responded to first-line treatment - You are in reasonably good health (ECOG score 0 or 1) - You have at least one measurable tumor that can be used to collect immune cells - Your life expectancy is at least 12 weeks **You may NOT be eligible if...** - You have uncontrolled cancer-related pain - You have a known mental illness, or a history of alcohol or drug abuse - You are pregnant, breastfeeding, or planning to become pregnant within 1 year - You received another experimental treatment within the past 4 weeks Talk to your doctor to see if this trial is right for you.